Skip to main content

Advertisement

SpringerLink
Log in

Further augmentation of molecular responses with dasatinib therapy in chronic myeloid leukemia patients who gained major molecular response under imatinib

  • Letter to the Editor
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

The Original Article was published on 26 May 2017

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Eskazan AE, Ozmen D (2017) Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events—is better always good? Expert Rev Hematol 10(7):583–586

    Article  CAS  PubMed  Google Scholar 

  2. Hughes TP, Ross DM (2016) Moving treatment-free remission into mainstream clinical practice in CML. Blood 128(1):17–23

    Article  CAS  PubMed  Google Scholar 

  3. Shiseki M, Yoshida C, Takezako N et al (2017) Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy. Int J Clin Oncol. 22:972–979

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Soverini S, Hochhaus A, Nicolini FE et al (2011) BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 118(5):1208–1215

    Article  CAS  PubMed  Google Scholar 

  5. Eskazan AE, Eyice D, Kurt EA et al (2014) Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion. Leuk Res 38(7):781–787

    Article  CAS  PubMed  Google Scholar 

  6. Ozgur Yurttas N, Sadri S, Keskin D et al (2015) Real-life data and a single center experience on dasatinib-induced pulmonary arterial hypertension in patients with Philadelphia chromosome-positive leukemias. Blood 126(23):4037 (Abstract)

    Google Scholar 

  7. Kirkizlar O, Eskazan AE (2016) Adverse events of tyrosine kinase inhibitors and their impact on quality of life in patients with chronic myeloid leukemia. Expert Rev Qual Life Cancer Care 1(5):353–359

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Fatih, Istanbul, Turkey

    Ahmet Emre Eskazan

Authors
  1. Ahmet Emre Eskazan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ahmet Emre Eskazan.

Ethics declarations

Conflict of interest

AEE has received honoraria from Novartis and Bristol-Myers Squibb.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eskazan, A.E. Further augmentation of molecular responses with dasatinib therapy in chronic myeloid leukemia patients who gained major molecular response under imatinib. Int J Clin Oncol 23, 400–401 (2018). https://doi.org/10.1007/s10147-017-1214-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-017-1214-y

Search

Navigation